Loading
A phase 2 trial of TROP2 PET in Breast cancer, run by Fudan University, now recruiting.
Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer is a phase 2 interventional study registered as NCT07471776 by Fudan University, with 45 participants planned, started 2026-03-11 and due to reach its primary completion in 2028-03-11. Interventions recorded: Sacituzumab Govitecan、Datopotamab deruxtecan、Sacituzumab tirumotecan, 68Ga-TROP2 PET/CT Imaging, 18F-FDG PET Imaging. Conditions recorded: Metastatic Breast Cancer ( HER2 Negative).
Linked to the technology TROP2 PET because the registry names it ("trop2 pet") among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/